Molecular pathogenesis of Alzheimer's disease: an update

A Sanabria-Castro, I Alvarado-Echeverría… - Annals of …, 2017 - karger.com
Dementia is a chronic or progressive syndrome, characterized by impaired cognitive
capacity beyond what could be considered a consequence of normal aging. It affects the …

NMDA and AMPA receptors dysregulation in Alzheimer's disease

P Babaei - European Journal of Pharmacology, 2021 - Elsevier
Alzheimer's disease (AD) is a progressive neurodegenerative condition characterized by
cognitive dysfunction and synaptic failure. The current therapeutic approaches are mainly …

Astrocytes as a therapeutic target in alzheimer's disease–comprehensive review and recent developments

M Rodríguez-Giraldo, RE González-Reyes… - International Journal of …, 2022 - mdpi.com
Alzheimer's disease (AD) is a frequent and disabling neurodegenerative disorder, in which
astrocytes participate in several pathophysiological processes including neuroinflammation …

Naturally occurring antioxidant therapy in Alzheimer's disease

AE Collins, TM Saleh, BE Kalisch - Antioxidants, 2022 - mdpi.com
It is estimated that the prevalence rate of Alzheimer's disease (AD) will double by the year
2040. Although currently available treatments help with symptom management, they do not …

Insights into the pathogenesis of neurodegenerative diseases: Focus on mitochondrial dysfunction and oxidative stress

A Jurcau - International journal of molecular sciences, 2021 - mdpi.com
As the population ages, the incidence of neurodegenerative diseases is increasing. Due to
intensive research, important steps in the elucidation of pathogenetic cascades have been …

Cerebrospinal fluid biomarkers of Alzheimer's disease: current evidence and future perspectives

DA McGrowder, F Miller, K Vaz, C Nwokocha… - Brain sciences, 2021 - mdpi.com
Alzheimer's disease is a progressive, clinically heterogeneous, and particularly complex
neurodegenerative disease characterized by a decline in cognition. Over the last two …

Role of calcium modulation in the pathophysiology and treatment of Alzheimer's disease

D Baracaldo-Santamaría, SS Avendaño-Lopez… - International journal of …, 2023 - mdpi.com
Alzheimer's disease (AD) is a chronic neurodegenerative disease and the most frequent
cause of progressive dementia in senior adults. It is characterized by memory loss and …

Mitochondria as a target for neuroprotection: role of methylene blue and photobiomodulation

L Yang, H Youngblood, C Wu, Q Zhang - Translational neurodegeneration, 2020 - Springer
Mitochondrial dysfunction plays a central role in the formation of neuroinflammation and
oxidative stress, which are important factors contributing to the development of brain …

Drug development for Alzheimer's disease: microglia induced neuroinflammation as a target?

Y Dong, X Li, J Cheng, L Hou - International Journal of Molecular …, 2019 - mdpi.com
Alzheimer's disease (AD) is one of the most common causes of dementia. Its pathogenesis
is characterized by the aggregation of the amyloid-β (Aβ) protein in senile plaques and the …

Glycogen synthase kinase 3β: a new gold rush in anti-Alzheimer's disease Multitarget Drug Discovery? Miniperspective

A De Simone, V Tumiatti, V Andrisano… - Journal of Medicinal …, 2020 - ACS Publications
Alzheimer's disease (AD), like other multifactorial diseases, is the result of a systemic
breakdown of different physiological networks. As result, several lines of evidence suggest …